Most recent guidelines advise targeting of lipid sensitivity 59% and specificity 63%, did not identify some very high-risk patients, and identified very lowering for primary prevention at those at high absolute coronary (CHD) risk. We compared the low-risk patients. Framingham-based methods using total cholesterol alone had sensitivity 90-98% and accuracy of five CHD risk assessment methods in identifying such patients: one based on total chospecificity 37-43%, and identified high-risk patients well, but identified some patients at very low risk. lesterol Á6.5 mmol/l plus two risk factors, and four based on the Framingham risk function (the Methods based on total5HDL cholesterol ratio had sensitivity 90-98% and specificity 60-63%, and did European Task Force chart and Sheffield table, both using total cholesterol and the New Zealand chart not identify incorrectly patients at very low CHD risk. Methods based on cholesterol threshold and and modified Sheffield table, both using total5HDL cholesterol ratio) for predicting CHD event risk counting of risk factors are too inaccurate for targeting drug therapy for primary prevention of CHD. Á2% per year, calculated by an independent risk function, PROCAM, in 126 treated hypertensive
Introduction
Recent outcome trials with HMG Co-A reductase ing the evidence, differences in policy, or differences in methods of implementing policy. 8 Interpretation inhibitors (statins) have radically changed therapeutic policies for cholesterol reduction. Secondary prevenof the evidence on statin treatment appears straightforward. Statins reduce major CHD events by 33% tion in those with established coronary or atherosclerotic disease and serum cholesterol Á5.0 mmol/l in those with LDL-cholesterol >3.2 mmol/l, and the relative risk reduction is constant between trials and is accepted as the first priority.1,2 However, guidance on statin treatment for primary prevention of coroin subgroups within trials.9,10 A constant relative risk reduction means that benefit from treatment is related nary heart disease (CHD) is not uniform.3 When recommendations of the British Hyperlipidemia to the absolute CHD risk. Absolute CHD risk therefore determines benefit to the individual (NNT), costAssociation,4 European Joint Task Force,5 US National Cholesterol Education Program6 (NCEP), or a effectiveness, the proportion of the population treated, and the total cost of statin treatment.9-11 A Standing Medical Advisory Committee7 (SMAC) are applied to British adults, they identify for treatment general consensus that statin treatment should be targeted at absolute CHD risk12 is echoed in all as few as 3.7% or as many as 13.5% of the population.3 Moreover, the individuals identified by recent guidelines.1,2,5,7
The guidelines differ principally in the policies set the different guidelines are not the same.3 These inconsistencies could reflect differences in interpretfor treatment, and on methods of identifying people to be treated. Two of them4,6 advise treatment based LDL-cholesterol rather than total cholesterol. The The appropriate policy on absolute CHD risk European and threshold plus counting methods threshold may properly differ between countries cannot target a CHD event risk of 3% per year, and depending on the population prevalence of CHD for the purpose of this analysis the Sheffield tables risk and availability of healthcare resources. 9 were recast to target a CHD event risk of 2% per Regardless of the policy adopted, what method will year.9 The CHD risk of each patient was estimated identify best those with the level of absolute CHD using all five risk assessment methods in accordance risk that warrants treatment? The method selected with published instructions on their use. The external needs to be simple for acceptance in ordinary standard was CHD risk calculated by the full practice, accurate, and valid for estimating absolute PROCAM risk function20 using age, blood pressure, CHD risk. When considering accuracy the balance smoking, diabetes, total and HDL-cholesterol, and between sensitivity and specificity is important. Statin family history. This analysis was restricted to men, treatment for primary prevention might now be because CHD risk in women could not be calculated justifiable on harm-benefit criteria at a CHD event by PROCAM at the time. CHD event risk was also risk as low as 0.6% per year. 16 The emphasis should calculated for men and women using the full therefore be to identify and treat all those above the specified CHD risk threshold because no harm will Framingham risk function.17 come from treating 'incorrectly' those below that threshold, provided their CHD risk is not very low.
Patients
The method of identifying people for treatment Complete data to enable calculation of CHD risk by should therefore have high sensitivity, with some the PROCAM and Framingham risk functions were sacrifice of specificity if necessary. We have comcollected prospectively for 216 consecutive treated pared the accuracy of five methods for estimating hypertensive patients who were aged 35-70 years, absolute CHD risk, one using a cholesterol threshold had total cholesterol Á5.5 mmol/l, and were free of plus simple counting of risk factors,4,6,13 and four vascular complications by clinical evaluation or ECG. based on the Framingham risk function.17 Two of
The variables measured and recorded were age, sex, the Framingham-based methods use total cholesterol smoking habit and family history (both by structured only (European Joint Task Force chart1,5 and Sheffield questions), blood pressure (mean of two measuretable10,15), and two use the total5HDL cholesterol ments), diabetes (fasting glucose >7.8 mmol/l, or ratio (New Zealand chart18 and modified Sheffield treated), and ECG left ventricular hypertrophy by table19). The validity of risk estimates based on the criteria used in Framingham. The characteristics of Framingham function was examined by comparing the study population are shown in Table 1 . The mean them to estimates of CHD risk by the PROCAM risk CHD event risk calculated by the full Framingham function, which is derived from a prospective study in a German population.20 function was 2.5% (SD 1.2%) per year in men Those based on total cholesterol alone5,10 had lower specificity (37% and 43%) than those using the total5HDL cholesterol ratio18,19 (60% and 63%). The Analysis two methods based on total5HDL cholesterol The principle endpoint was the accuracy of the ratio18,19 identified men with a mean CHD event different risk assessment methods in men for prerate of 3.0% per year for treatment, and with rates dicting a CHD event risk Á2.0% per year calculated of 0.7 and 1.0% per year in those not treated. The by the full PROCAM risk function. The predictive scatters for the cholesterol threshold plus risk factor value of HDL-cholesterol (in the total5HDL cholescounting method and the Sheffield tables based on terol ratio) was examined further by comparing the total cholesterol or the total5HDL cholesterol ratio accuracy of Sheffield tables based on total cholesterol are shown in Figure 1 . The cholesterol threshold plus alone (using population mean values for HDL-cholesrisk factor counting method failed to treat patients terol) or the total5HDL cholesterol ratio for estimatwith high and even extremely high CHD risk, and ing CHD event risk Á3.0% per year calculated by often identified for treatment patients at very low the full Framingham risk function. Sensitivity, specifi-CHD risk, below 0.6% per year. This method failed city and 95%CIs were calculated by standard to classify five men for treatment despite them methods. 21 actually having an annual CHD risk >5% by the PROCAM function. These men had serum cholesterol <6.5 mmol/l but had numerous other risk factors.
Results
All five men were >60 years old; three had systolic blood pressure Á160 mmHg; two were smokers;
Comparison of methods four were diabetic; three had a positive family history of ischaemic heart disease; and four had serum HDL The sensitivity and specificity for each method, and concentration ∏1.0 mmol/l. The table based on total the mean CHD event risks in those treated or not cholesterol alone failed to treat some patients above treated, are shown in Table 2 . The method based on the 2% per year threshold, and also treated patients cholesterol threshold Á6.5 mmol/l plus two CHD with CHD risk below 0.6% per year. The table risk factors had a sensitivity of 59% and specificity incorporating HDL-cholesterol in the ratio treated 63% versus PROCAM, with mean annual CHD event almost all patients with CHD event risk Á2% per risk of 2.7% for those treated and 1.9% for those year, and did not treat any patient with CHD risk not treated. All four methods based on Framingham had sensitivity between 90-98% for predicting below 0.6% per year. Importance of total5HDL cholesterol ratio it fails to treat many patients who are above the Figure 2 shows the outcome of targeting a CHD preset threshold. Most but not all of the high-risk event risk of 3% per year, calculated by the full men not treated have CHD event risks between Framingham function, using Sheffield tables based 3-4% per year. on total cholesterol alone or the total5HDL cholesterol ratio in men and women combined. The latter table incorporates all the variables in the Framingham Discussion risk function, with only blood pressure approximated, and as anticipated the sensitivity (100%) and specifi-
The Framingham risk function has been available for several years, but was used little in ordinary city (94%) are very high. Those identified for treatment have a mean CHD event risk much higher practice until recently. In Britain a national survey of local policies for cholesterol management in 1994 than that of those untreated (4.1% vs. 1.8% per year). Use of total cholesterol alone also identifies showed that only 2% included a formal risk assessment method.22 However, methods based on high (3.6%) and low (1.5%) risk groups, has no important effect on specificity (98%), but reduces
Framingham are now in widespread use. Reasons include acceptance that individual benefit, costthe sensitivity markedly to 45%. Virtually all those A recent comparison of three risk-assessment methods (NCEP guidelines,6 Sheffield table using Some guidelines use thresholds of total or LDLcholesterol along with simple counting of risk factotal cholesterol,10 and European guidelines5) was carried out in a series of 570 patients without clinical tors,4,6 and indeed this policy is still advocated in the Monthly Index of Medical Specialities (MIMS),26 evidence of atherosclerosis referred to a lipid clinic.28 This showed that the different methods varied marka prescribing aid widely used by British doctors. In our study, this method was distinctly less accurate edly in their assessment of CHD risk. However one of the methods tested10 was not used correctly, and than Framingham-based methods that count and weight risk factors for CHD. It failed to treat patients in addition, specificity was entirely ignored. The present study confirms the high sensitivity of the with high and even extremely high CHD risk, while identifying for treatment many with a CHD event Joint European Task Force chart, but shows that it has very low specificity. risk below 0.6% per year, the present limit of outcome trial evidence for statins. 16 Low accuracy
The comparison of Framingham-based methods against CHD risk calculated by PROCAM shows that was reported in previous studies,23,27 and accuracy declines with increasing age beyond 35 years in the Framingham function has external validity, adding to a large body of evidence that it predicts men and 55 years in women.27 Use of LDL-cholesterol or total cholesterol thresholds plus risk factor CHD risk accurately in British and northern European populations despite secular changes in CHD incidcounting identifies a high proportion of the adult population for statin treatment,3,28,29 for example ence.31 The simple Framingham-based methods are all capable of detecting most high-risk individuals consensus alone in three, but this was not so for guidance based on the Sheffield table.7,10 This was for treatment, but incorporation of HDL-cholesterol, as the total5HDL cholesterol ratio, greatly enhances developed after the implications of statin treatment at different levels of CHD risk had been set out the accuracy of risk prediction with either the PROCAM or Framingham risk function as the gold explicitly for examination and debate,9,10 an important fact that has been overlooked entirely by some.3,34 standard. The Framingham function appears robust to many simplifications or approximations, for Statin prescribing in Britain is not constrained by benefit to the individual (NNT) or even primarily by example omitting left ventricular hypertrophy or categorizing blood pressure, but not to omission of cost-effectiveness. The main constraint by far is the high proportion of the adult population likely to HDL-cholesterol concentration. British doctors may be relatively unfamiliar with the total5HDL cholesneed statin treatment and, stemming from this, the very high total cost of treatment and the resource terol ratio, and many laboratories do not measure or report this parameter routinely, but the accuracy of implications for primary care.9,10 Complete implementation of statin treatment for secondary preven-CHD risk prediction and statin prescribing would be greatly enhanced by its use.32 LDL-cholesterol is tion plus primary prevention at a CHD event rate Á3% will entail treating about 8% of all adults,9 favoured in the US and by some specialists in Britain and Europe because it is the proximate cause of and some believe that even this is not feasible. This policy still seems appropriate for the UK, but treat-CHD. However, use of LDL-cholesterol rather than total cholesterol does not improve risk prediction by ment at lower CHD risk levels may be appropriate in the future, and at present for other populations the Framingham function,14 and therefore offers no advantage.
with a lower prevalence of CHD risk factors or CHD risk. The SMAC guidance7 was based on a Sheffield Any of the Framingham-based methods studied will improve the prescribing accuracy of doctors table using total cholesterol alone and cholesterol threshold Á5.5 mmol/l, which actually extrapolated who are unable or unwilling to use the full Framingham risk function. The New Zealand chart18 beyond the evidence available then for primary prevention. High specificity at the expense of sensitestimates cardiovascular risk rather than CHD risk, a fact not widely appreciated in practice or even by ivity (Figure 2 ) was appropriate at that time, but is now too conservative in light of new evidence on experts. Despite this, it estimates CHD risk accurately, because cardiovascular risk and CHD risk primary prevention. 16 The total cholesterol threshold for treatment should be lowered to Á5.0 mmol/l,16 correlate highly in the Framingham function, but with a ratio of approximately 453. Use of the New and a method with high sensitivity for CHD risk prediction is required, at the expense of specificity Zealand chart at a threshold of 2.0% per year in this study actually targets a CHD event rate of about if necessary. Methods based on the total5HDL cholesterol ratio (Figure 2 ) should be preferred. 1.5% per year. The Sheffield tables10,15,19 are designed to assess CHD risk after control of any hypertension, because antihypertensive treatment is currently more cost-effective than statin treatment.
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They will be less accurate when hypertension is to be examined in much larger and unselected samples of the general population. 
